Literature DB >> 2853960

Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis.

J G Kelly1, G D Doyle, M Carmody, D R Glover, W D Cooper.   

Abstract

1. Lisinopril and enalapril were administered as 2.5 mg single doses and as eight single daily 2.5 mg doses to separate groups of six patients with chronic renal failure. Patients were receiving regular haemodialysis. 2. In the absence of haemodialysis, the decline in plasma concentrations of lisinopril and enalaprilat was extremely slow and plasma concentrations were generally high. 3. Haemodialysis had large effects on plasma concentrations of lisinopril and enalaprilat. A 4 h period reduced plasma concentrations of both drugs by around one-half and often by significantly more than this. Even 1 or 2 h of haemodialysis had significant effects. 4. Haemodialysis plasma clearance was similar for both drugs with mean values of the order of 40 ml min-1. Clearance did not markedly differ when measured after 1, 2 or 4 h of haemodialysis or after single or multiple doses of lisinopril or enalapril. 5. The design of dosage regimens of both lisinopril and enalapril for patients with severe renal impairment or chronic renal failure should take into consideration the use and effects of haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2853960      PMCID: PMC1386595          DOI: 10.1111/j.1365-2125.1988.tb05319.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Lisinopril in hypertensive patients with and without renal failure.

Authors:  B A van Schaik; G G Geyskes; P Boer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Pharmacokinetics of enalapril in normal subjects and patients with renal impairment.

Authors:  J G Kelly; G Doyle; J Donohue; M Laher; M J Vandenburg; W J Currie; W D Cooper
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

3.  Intra-individual comparison of captopril and enalapril in patients undergoing regular haemodialysis.

Authors:  J Sennesael; D Verbeelen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Enalapril maleate and a lysine analogue (MK-521): disposition in man.

Authors:  E H Ulm; M Hichens; H J Gomez; A E Till; E Hand; T C Vassil; J Biollaz; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

5.  The effect of renal function on enalapril kinetics.

Authors:  D T Lowenthal; J D Irvin; D Merrill; S Saris; E Ulm; S Goldstein; M Hichens; L Klein; A Till; K Harris
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

  5 in total
  12 in total

Review 1.  Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.

Authors:  D A Sica; T W Gehr; A Fernandez
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Massive Atenolol, Lisinopril, and Chlorthalidone Overdose Treated with Endoscopic Decontamination, Hemodialysis, Impella Percutaneous Left Ventricular Assist Device, and ECMO.

Authors:  C William Heise; David Beutler; Adam Bosak; Geoffrey Orme; Akil Loli; Kimberlie Graeme
Journal:  J Med Toxicol       Date:  2015-03

Review 3.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 5.  Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

7.  Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.

Authors:  D A Sica; R E Cutler; R J Parmer; N F Ford
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

8.  The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril.

Authors:  A Guérin; G Resplandy; S Marchais; F Taillard; G London
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

10.  The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients.

Authors:  T W Gehr; D A Sica; D M Grasela; K L Duchin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.